EcoDrugPlus

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 6

Ensembl ID : ENSCHAG00000003265
Gene Symbol: CACNG6
3 Cross references
177 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 7

Ensembl ID : ENSCHAG00000003313
Gene Symbol: CACNG7
1 Cross references
190 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 8

Ensembl ID : ENSCHAG00000003285
Gene Symbol: CACNG8
3 Cross references
163 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 A

Ensembl ID : ENSCHAG00000009028
Gene Symbol: CACNA1A
1 Cross references
199 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 B

Ensembl ID : ENSCHAG00000009515
Gene Symbol: CACNA1B
1 Cross references
215 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 D

Ensembl ID : ENSCHAG00000021153
Gene Symbol: CACNA1D
1 Cross references
210 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSCHAG00000006749
Gene Symbol: CACNA1E
1 Cross references
216 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 G

Ensembl ID : ENSCHAG00000025802
Gene Symbol: CACNA1G
1 Cross references
197 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 I

Ensembl ID : ENSCHAG00000005310
Gene Symbol: CACNA1I
1 Cross references
191 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSCHAG00000024208
Gene Symbol: CNR1
3 Cross references
153 Possible Orthologues:

Cannabinoid Receptor 2

Ensembl ID : ENSCHAG00000016500
Gene Symbol: CNR2
1 Cross references
196 Possible Orthologues:

Carbonic Anhydrase 12

Ensembl ID : ENSCHAG00000006342
Gene Symbol: CA12
1 Cross references
215 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).